Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adenosine for myocardial protection in warm blood cardioplegia during minimally invasive mitral valve surgery
NL-OMON42535Phase 2Active, not recruiting
- Sponsor
- Amphia Ziekenhuis
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of adenosine in cardiac disease (2 arms), sponsored by Amphia Ziekenhuis. Primary endpoint: 6-hour postoperative cardiac troponin T. Started Feb 2016; status: active, not recruiting.
02
Drugs
adenosine
03
Conditions
cardiac disease
Beyond the preview
Go deeper on NL-OMON42535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42535.